Sangamo Therapeutics Regains Rights to Giroctocogene Fitelparvovec Following Pfizer's Decision to End Collaboration

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced it will regain development and commercialization rights to giroctocog...

December 31, 2024 | Tuesday | News
IDEAYA Biosciences Acquires Global Rights to SHR-4849 DLL3-Targeting ADC in $1 Billion Agreement with Hengrui Pharma

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, an...

December 30, 2024 | Monday | News
Hoth Therapeutics Secures Exclusive Patent License from VA and Emory University to Tackle Obesity and Related Diseases

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Ma...

December 27, 2024 | Friday | News
AusperBio Therapeutics Secures $73M Series B Funding to Advance Targeted Therapies for Chronic Hepatitis B

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to ...

December 27, 2024 | Friday | News
Sanofi and SK bioscience Expand Collaboration to Develop Next-Generation Pneumococcal Vaccines for Global Impact

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and...

December 24, 2024 | Tuesday | News
Valneva and Serum Institute of India Partner to Deliver Asia’s First Single-Shot Chikungunya Vaccine

  Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world’s...

December 19, 2024 | Thursday | News
Catalent’s $16.5 Billion Acquisition by Novo Holdings Sets the Stage for Transforming Global Healthcare

Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S...

December 19, 2024 | Thursday | News
A2A Pharmaceuticals Advances Clinical Trials for AO-252, TACC3 Inhibitor, in Ovarian, TNBC, and Endometrial Cancers

A2A Pharmaceuticals, Inc. ("A2A" or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies...

December 18, 2024 | Wednesday | News
SK Biopharmaceuticals Forms Strategic Research Collaboration with ProEn Therapeutics to Advance Radiopharmaceutical Oncology Pipeline

SK Biopharmaceuticals, a biotech company focusing on the research, development and commercialization of treatments for disorders of the central nervous sys...

December 17, 2024 | Tuesday | News
Jaypirca® (Pirtobrutinib) Gains Approval in China for Relapsed or Refractory Mantle Cell Lymphoma

Jaypirca®, a highly selective kinase inhibitor, utilizes a novel non-covalent binding mechanism to re-establish BTK inhibition in mantle cell lymphoma ...

December 16, 2024 | Monday | News
Nona Biosciences Partners with Kodiak Sciences to Advance Multi-Target Antibodies for Ophthalmic Diseases

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody disc...

December 10, 2024 | Tuesday | News
Amgen’s BLINCYTO® Significantly Improves Disease-Free Survival in Pediatric B-ALL, Redefining Standard of Care

Amgen (NASDAQ:AMGN) announced new data demonstrating that adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease...

December 09, 2024 | Monday | News
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Partner to Advance Groundbreaking ALS Therapy

- Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying patholo...

December 05, 2024 | Thursday | News
Duality Biologics Signs Exclusive Option Agreement with GSK for ADC Candidate DB-1324 in Gastrointestinal Cancer

 Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjuga...

December 04, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close